$121M lat­er, Langer-backed Se­lec­ta rais­es $70M more from its IPO

Se­lec­ta Bio­sciences ($SELB) land­ed on Nas­daq with a slight limp, rais­ing $70 mil­lion af­ter pric­ing a bumped-up batch of shares at $14 — the low end of its range.

In this mar­ket, for a biotech that isn’t di­rect­ly en­gaged in gene edit­ing, that’s cause for cel­e­bra­tion, though Se­lec­ta ex­ecs may choose from the less ex­pen­sive brands of Cham­pagne for the go­ing-pub­lic par­ty.

MIT in­ves­ti­ga­tor Robert Langer, Omid Farokhzad and Ul­rich von An­dri­an of the Har­vard Med­ical School pro­vid­ed the sci­en­tif­ic fire­pow­er re­quired to launch Wa­ter­town, MA-based Se­lec­ta, which has been steadi­ly ad­vanc­ing a new syn­thet­ic nanopar­ti­cle tech­nol­o­gy to block an un­want­ed im­mune sys­tem at­tack, thwart­ing an an­ti-drug an­ti­body re­sponse that can be kicked up by a va­ri­ety of bi­o­log­ics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA